Genome-wide significant variants associated with combined risk for major psychiatric 39 disorders on chromosome 10q24 affect the expression of the cytosolic 5'-nucleotidase II 40 (NT5C2, cN-II) in population controls, implicating it as a psychiatric susceptibility gene. Risk 41 alleles are associated with reduced expression of this gene in the developing and adult 42 brain, but the resulting neurobiological risk mechanisms remain elusive. In this study, we 43 provide further evidence for the association of NT5C2 with psychiatric disorders, and use a 44 functional genetics approach to gain a deeper understanding of the function of this risk gene 45 in the nervous system. NT5C2 expression was significantly reduced in the post-mortem 46 brain of schizophrenia and bipolar disorder patients, and its protein predominately 47 expressed in neurons within the adult brain. Using human neural progenitor cells (hNPCs), 48 we found that NT5C2 expression peaked at the neural progenitor state, where the encoded 49 protein was ubiquitously distributed through the cell. NT5C2 knockdown in hNPCs elicited 50 transcriptomic changes associated with protein translation, that were accompanied by 51 regulation of adenosine monophosphate-activated protein kinase (AMPK) signalling and 52 ribosomal protein S6 (rpS6) activity. To identify the effect of reduced neuronal NT5C2 53 expression at a systems level, we knockdown its homologue, CG32549, in Drosophila 54 melanogaster CNS. This elicited impaired climbing behaviour in the model organism.
RNA and protein isolation and quantification
To identify gene and protein expression and phosphorylation differences associated with 157 NT5C2 function, we isolated total RNA or protein from in vitro cultures using TRI Reagent and total rpS6 (54d2) and phospho-rpS6 (Ser235/Ser236) (Cell Signalling, Danvers, 165 Massachusetts, United States).
167
Confocal microscopy 168 We imaged fluorescently labelled cultures or brain sections using confocal microscopy to 169 identify the distribution of NT5C2 in the adult brain, and the sub-cellular distribution of this 170 protein in hNPCs. Imaging was performed at the Wohl Cellular Imaging Centre, King's 171 College London, using a Nikon A1R (Nikon, Amsterdam, Netherlands) or a Leica SP5 172 Confocal Microscope (Leica, Wetzlar, Germany). Images were taken as z-stacks of 8-10 173 plans, and exported to Fiji, where background subtracted images and maximum intensity 174 projections were generated. To identify cell-type expression of NT5C2 in the brain, co-175 localisation was defined as percentage of co-localised clusters relative to total number of 176 clusters detected per image. High throughput analysis was performed using an ImageJ 177 macro 26 previously used for co-localisation investigations 27 197 To test the role of NT5C2 in psychomotor behaviour in D. melanogaster, the D. To identify differences between more than two independent groups, we used one-way 208 ANOVAs followed by Tukey post hoc tests if values were normally distributed (e.g. co-209 localisation between NT5C2 and different markers, or the effect of two independent siRNAs 210 in hNPCs relative to control cultures); or Kruskal-Wallis tests followed by Dunn's post hoc 211 tests, if values were not normally distributed (e.g.: the effect of the knockdowns on total and 212 phosphorylated levels of AMPK and rpS6). To compare differences between two groups, we 213 performed t-tests if values were normally distributed (e.g. expression differences between 214 hNPCs and cultures, the effect of the knockdown or overexpression in hNPCs or HEK293T); 215 or Mann-Whitney tests if they were not normally distributed (e.g. survival and climbing 216 success ratios associated with CG32549 knockdowns in Drosophila); correction for multiple 217 testing was performed using the Bonferroni method. The Fisher's exact test to calculate 218 significance of the gene overlaps was performed in R using the package 'GeneOverlap'.
Fly stocks and motility test

219
Statistical analyses were performed in R or in IBM SPSS. 
Results
222
NT5C2 expression is reduced in the brain of schizophrenia and bipolar disorder 223 patients 224 We previously demonstrated that NT5C2 expression is reduced in the brain of unaffected 225 controls due to cis-regulatory effects associated with psychiatric risk alleles located on 226 chromosome 10q24 3 . To study the expression of this gene in a psychiatric cohort, we 227 analysed RNA-sequencing (RNA-seq) data from the hippocampus of patients diagnosed (Supplementary Tables 7-12 ). This analysis revealed that NT5C2 was less 232 expressed in SCZ (P < .001, false discovery rate (FDR) corrected P = .01, fold-change = 233 0.56) and BD patients (P < .001, corrected P = .02, fold-change = 0.69), but not in MDD 234 patients (P > .05) ( Figure 1A) . These findings corroborate a role for NT5C2 in mediating 235 susceptibility to psychiatric disorders, particularly those associated with psychotic features.
237
Expression of NT5C2 is enriched in neurons relative to glial cells in the adult brain 238 To understand how genetic variation affecting NT5C2 expression may confer risk for 239 psychiatric disorders, we investigated which neuronal cell types expressed this gene. First, 240 we examined single-cell RNA-seq data from the mouse cortex 30 to predict which cell type(s) 241 highly expressed NT5C2. This analysis revealed a significant difference in the cell-type 242 specific expression of NT5C2 within neuronal and non-neuronal cells (One-way ANOVA, F 243 (3, 1008) = 11.11, P < .001). Post-hoc analysis confirmed that NT5C2 is more abundant in 244 neurons and interneurons than astrocytes (Tukey post hoc tests: P < .001 for all 245 comparisons; Supplementary Figure 1 ).
247
To investigate whether this distribution pattern also occurs in humans, we performed a 248 series of immunocolocalisation experiments using autopsy brain tissue and confocal 249 microscopy. We confirmed specificity of an antibody raised against NT5C2 by using it to Figure 3) . However, we noted that not all putative 257 glial cells expressed NT5C2 (red arrows; Supplementary Figure 3) . Therefore, to confirm 258 this, we quantified the cell type-specific expression of NT5C2 by measuring the co- (MAP2: 7.48% ± 2.02 (standard deviation); PARVALB: 6.89% ± 2.09; GFAP: 3.13% ± 1.09; 269 IBA1: 1.44% ± 0.93; Tukey post hoc tests: P < .001 for all comparisons; Figure 1F ), but not 270 within these categories (i.e., GFAP vs. IBA1, P > .05). These data corroborate the single-271 cell RNA-seq data from the mouse brain (Supplementary Figure 1) , and confirm our 272 qualitative observations using immunoperoxidase staining (Supplementary Figure 3) . 273 Overall, these data suggest that whilst NT5C2 expression at the message and protein level 274 is found in both neurons and glial cells, it is clearly enriched in neurons relative to glia. This 279 The role of NT5C2 in psychiatric disorders commence during neurodevelopment 3 , a period 280 underscored by a large number of concurrent and ongoing complex process, implicated in 281 all major psychiatric disorders. Indeed, assessment of the Human Brain Transcriptome 282 Atlas 33 (Figure 2A) (Figure 2B) , indicating that NT5C2 may also play a role in immature 292 neurons. These data are consistent with a psychiatric risk mechanism mediated by NT5C2 293 expression which starts during neurodevelopment and persists during adult life 3 . Next, we assessed the sub-cellular distribution of NT5C2 in hNPCs derived from human 296 induced pluripotent stem cell (hiPSC) and CTX0E16 cells. First, we ectopically expressed a 297 myc-tagged NT5C2 construct in hiPSC-NPCs. This revealed that ectopic myc-NT5C2 was 298 abundantly expressed in the cell soma and was present in punctate structures along neurites 299 ( Figure 2C) . We further confirmed the ability of our antibody raised against NT5C2 to detect 300 myc-NT5C2 (Supplementary Figure 4) . Next, we examined the distribution of endogenous 301 NT5C2 in hNPCs derived from hiPSCs ( Figure 2D) and from the CTX0E16 cell line ( Figure   302 2E). Similar to the distribution of ectopic protein, endogenous NT5C2 was found dispersed 303 throughout the cell, and was present in punctate structures within the cell soma and along 304 neurites; virtually all imaged cells expressed NT5C2. Taken together, these data suggest 305 that NT5C2 is highly expressed and ubiquitously distributed in hNPCs. (Figure 3B) . This analysis revealed that NT5C2 expression was significantly 320 14 affected by siRNA treatment (One-way ANOVA, F (2, 8) = 13.45, P = .003). Tukey post hoc 321 tests revealed a mean ~27% decrease in NT5C2 expression in knockdown conditions 322 (siRNA A: 71.00 ± 13.92, P = .004; siRNA B: 75.10 ± 7.29, P = .004). We assessed the Figures 3E and F) . To reduce off-target effects associated with individual siRNAs 34 , 331 we identified the concordant transcriptomic effects shared between both siRNA treatments.
NT5C2 is highly expressed and ubiquitously distributed in hNPCs
332
This analysis revealed an overlap of 69 genes (Figure 3G) , which is unlikely to occur by 333 chance given the number of genes tagged in the microarray (n = 21,196 genes; Fisher's 334 exact test, P < .001, Jaccard index < .001, odds ratio = 2.6; gene list in Supplementary 335 Table 13 ). This list was subdivided by directionality of effect, and the up-and downregulated 336 network topologies were calculated using GeneMania 28 (Supplementary Figure 5) . This Table 14 ). The top upregulated GO term suggested the involvement of 345 NT5C2 in cell adhesion (GO:0005924 cell-substrate adherens junction), but this term did not 346 15 survive multiple testing correction (q > .05). We used RT-qPCR to validate a panel of gene 347 expression changes detected in the microarray analysis which are functionally related to the 348 GO terms, to support their association with NT5C2 (Supplementary Figure 6) . These NT5C2 regulates AMPK and ribosomal protein S6 (rpS6) phosphorylation 358 Protein translation has been extensively implicated in psychiatric disorders [39] [40] [41] , but the 359 mechanisms leading to disruptions in this process remain elusive. As our transcriptomic data 360 indicated that reducing NT5C2 expression could impact translation machinery, we were 361 interested in investing whether this could be associated with an alteration in protein 362 translation. One mechanism via which NT5C2 expression may impact protein translation is 363 through AMPK signalling. For example, in glioblastoma cells, NT5C2 has been shown to Figure 4A) . These findings corroborate 378 a functional association between NT5C2 and AMPK signalling in hNPCs, and further 379 suggest that this kinase pathway may be dysregulated in psychiatric disorders.
381
As AMPK signalling has been linked with the regulation of protein synthesis [42] [43] [44] , and owing 382 to our transcriptomic data, we next tested whether the NT5C2 knockdown had an effect on 383 the phosphorylation of the ribosomal protein S6 (rpS6) at residues Ser235/Ser236.
384
Assessment of rpS6 phosphorylation is widely used to monitor activation of mammalian 385 target of rapamycin complex 1 (mTORC1) signalling and can be used as a proxy to estimate 386 protein translation in neurons 45 . Knockdown of NT5C2 did not alter levels of total rpS6 levels 387 (Kruskal-Wallis test, H(3) = 0.04, P > .05; Figure 4B ). However, a significant increase in To support the association between NT5C2, AMPK signalling and rpS6 activity, we carried 397 out complementary experiments in HEK293T cells using a pNT5C2-myc overexpression 398 plasmid. Exogenous expression of NT5C2 in HEK293T cells resulted in a mean ~64% 399 decrease in phosphorylated AMPK-alpha (independent t-test; control: 223.00 ± 76.99, 400 overexpression: 81.05 ± 30. 14, t(15) = 4.88, P < .001, Bonferroni corrected P < .001; Figure   401 4C), whilst no difference in total AMPK levels were observed (t(12) = 1.16, P > .05; Figure   402 4C). These data are consistent with our data indicating that NT5C2 is a negative regulator 403 of AMPK signalling. Next, we examined levels of total and phosphorylated rpS6 in the 404 presence or absence of ectopic NT5C2. This revealed a mean ~28% decrease in total rpS6 405 abundance (control: 159.10 ± 48.52, overexpression: 108.8 ± 48.52, t(16) = 2.88, P = .011, 406 corrected P = .044 ; Figure 4C) , and a mean 300% increase in rpS6 phosphorylation 407 (control: 31.03 ± 10.66, overexpression: 124.10 ± 8.20, t(16) = 20.76, P < .001, corrected P 408 < .001; Figure 4C ). This effect of exogenous NT5C2 on rpS6 phosphorylation was opposite 409 to that observed in hNPCs, corroborating the complex nature of the intracellular cascades Our NT5C2 knockdown studies in hNPCs, together with the developmental profile of the 419 gene in human brain (Figure 2A) support an important role for NT5C2 in early brain 420 development. However, these molecular studies do not afford an insight into the potential 421 impact of reduced developmental expression of NT5C2 at a systems level. Interestingly, the 422 NT5C2 protein shares 60.5% sequence identity and 80.2% sequence similarity with the D. 423 melanogaster homologue, CG32549 (Supplementary Figure 7) , suggesting that they likely 424 18 exert the same or similar function. Thus, we reasoned that it would be possible to gain an 425 insight into the functional impact of reduced NT5C2 expression in vivo, by modelling the 426 knockdown of CG32549 on a complex and polygenic behaviour, such as climbing. This is a 427 polygenic psychomotor trait driven by an interaction between cognitive function and physical 428 activity, which is easily observable and measurable in D. melanogaster, and that has been 429 previously used to study the functional impact of gene mutations in D. melanogaster 29, 46 , 430 including those associated with psychiatric and neurodegenerative risk 47 .
432
To test the role of CG32549 in vivo, three knockdown fly lines were engineered using the 433 Gal4 upstream activating sequence (UAS-Gal4) system 48 , to artificially reduce CG32549 434 expression either ubiquitously throughout the whole body, specifically in the central nervous 435 system (CNS), or in the gut. This was achieved by crossing a CG32549-RNAi line with flies 436 containing the GAL4-driven promoters of ACT5C, ELAV, or GUT, respectively (Figure 5A) . 437 The Gal4-UAS system is most active at 29°C 49 , and therefore crosses were incubated at 438 this temperature from the pupal stage to elicit the strongest knockdown of CG32549 at this Whitney test, P > .05, n = 6; Figure 5C ). There was, however, a mean ~20% reduction in (Figure 3) , we 471 hypothesise that this mechanism may also occur in the adult brain, although it may be 472 susceptible to additional regulatory mechanisms. We further hypothesise that the psychiatric 473 risk mechanism pertaining NT5C2 expression in the adult brain is more likely to occur in 474 neurons, where this protein is more expressed relative to glial cells (Figure 1 ). This is 475 consistent with the recent suggestion that expression of psychiatric risk genes is cell-type 476 20 specific, with particular enrichment of neuronal cell type 32 . Ultimately, the association 477 between NT5C2 function and protein translation regulation corroborates the idea that this 478 gene serves a fundamental role in cell biology, as it is implicated in a multitude of disease 479 states 1, 2, 4-9 .
481
The transcriptomic analysis of the knockdown in hNPCs also revealed that NT5C2 may 482 govern genes that regulate the cytoskeleton (Figure 4) . Changes to the cytoskeleton have 483 been previously implicated in psychiatric disorders 51 , but these significantly depend on the 484 translational machinery 52 . Protein translation is such a finely regulated process; it is in part 485 modulated by AMPK signalling 53-55 and rpS6 activity 45, 56, 57 , and has been vastly implicated 486 in psychiatric disorders [39] [40] [41] considering the heterogeneity inherent to all psychiatric conditions. We partly addressed this 503 issue by controlling for gene expression changes associated with the effect of 504 demographics; this analysis could be further improved by significantly increasing sample 505 size. Second, we obtained a modest knockdown in the loss-of-function experiment in 506 hNPCs, which is likely due to the proliferative nature of these cells. We partly addressed this 507 issue by testing hypotheses generated based on the microarray results using western 508 blotting and a different cell type (HEK293T cells; Figure 4) , which supported our findings.
510
Our results provide clues to the mechanism via which genetic variation affecting NT5C2 511 expression may confer risk for psychiatric disorders. While functional studies in vitro or using 512 model organisms cannot entirely capture the complex nature of these conditions, we 513 anticipate that further work on this and other susceptibility genes may lead to the 514 identification of converging risk mechanisms, which may reveal novel drug targets amenable 515 for therapeutic intervention, or biomarkers for these conditions. 
